Inebilizumab 伊奈利珠单抗|cas:1299440-37-1|西域试剂

Inebilizumab 伊奈利珠单抗,95.0%

产品编号：Bellancom-P99113| CAS NO：1299440-37-1

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P99113	￥3000.00	杭州北京（现货）
Bellancom-P99113	￥7800.00	杭州北京（现货）
Bellancom-P99113	￥12500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Inebilizumab 伊奈利珠单抗

产品介绍

Inebilizumab 是一种抗 CD19 单克隆抗体 (mAb)，对 B 细胞具有增强的抗体依赖细胞介导的细胞毒性。 Inebilizumab 可用于多发性硬化和视神经脊髓炎的研究。

生物活性

Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research.

体外研究

Inebilizumab is derived from the mouse anti-human mAb HB12b, which had already shown impressive activity in depletion of B cells in transgenic mice carrying the human CD19 gene (hCD19 Tg).
Inebilizumab potently depletes CD19-expressing B cells, including primary human B cells, B cell lines derived from multiple tumor types, and neoplastic B cells.
Inebilizumab demonstrates equal or better activity than Rituximab (HY-P9913) in depletion of human primary B cells in autologous ADCC assays and shows potent ADCC activity against human in vitro-differentiated and primary plasma cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Inebilizumab (MEDI-551) (0-10 mg/kg; i.v.; once) depletes B cells from blood and spleen by mouse macrophages in vivo and phagocytosis of murine B cells ex vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	huCD19/CD20 double Tg mice
Dosage:	0.5, 2, or 10 mg/kg
Administration:	Tail vein injection, once
Result:	Depleted B cells from blood and spleen, B-cell depletion in blood and spleen was maintained for more than 2 weeks after a single 10 mg/kg administration (better than Rituximab). Resulted in a substantial reduction (on average by 91.4% by day 3) in BM B220+muCD19+ B cells. Led to depletion of B cell by mouse macrophages.

体内研究

Inebilizumab (MEDI-551) (0-10 mg/kg; i.v.; once) depletes B cells from blood and spleen by mouse macrophages in vivo and phagocytosis of murine B cells ex vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	huCD19/CD20 double Tg mice
Dosage:	0.5, 2, or 10 mg/kg
Administration:	Tail vein injection, once
Result:	Depleted B cells from blood and spleen, B-cell depletion in blood and spleen was maintained for more than 2 weeks after a single 10 mg/kg administration (better than Rituximab). Resulted in a substantial reduction (on average by 91.4% by day 3) in BM B220+muCD19+ B cells. Led to depletion of B cell by mouse macrophages.